<DOC>
	<DOCNO>NCT02843100</DOCNO>
	<brief_summary>The modified-Exclusive Enteral Nutrition ( mEEN ) open label randomize control pilot trial mild severe Crohn 's Disease patient . The purpose study determine whether induction remission maintenance remission achieve new dietary strategy involve 2 week Exclusive Enteral Nutrition ( EEN ) Modulen 12 week exclusion diet involve select table food . This novel approach compare gold standard dietary regime involve 8 week EEN .</brief_summary>
	<brief_title>Diet Induction Maintenance Remission Re-biosis Crohn 's Disease</brief_title>
	<detailed_description>Rational : Exclusive enteral nutrition ( EEN ) establish difficult perform method induction remission use maintenance remission . It entail drink liquid formula 8 week . Refusal use adhere therapy uncommon lead use non- dietary strategy child include steroid immunosuppression . The Crohn 's Disease Exclusion Diet ( CDED ) partial enteral nutrition show effective child mild moderate disease . The investigator develop maintenance strategy use CDED . Objectives : To prove induction remission maintenance remission achieve new dietary strategy involve 2 week EEN Modulen 12 week exclusion diet involve select table food . Methods : Open label randomize control pilot trial compare two week EEN follow CDED Partial Enteral Nutrition ( PEN ) , 8 week EEN follow PEN free diet . The study include control group healthy child microbiome study . Population : Age 8-18 year mild severe active Crohn 's disease define 15 &lt; Pediatric Crohn 's Disease Activity Index ( PCDAI ) &lt; 47.5 . Time frame : The induction remission phase last 8 week follow maintenance phase period 24 week . Expected outcomes significance : If method prof equivalent EEN , duration use EEN two week , allow patient access dietary therapy . More importantly , study also evaluate two maintenance strategy first evaluate re-biosis .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Inclusion criterion : 1 . Established diagnosis Crohn 's disease . 2 . Patients mild severe active Crohn 's disease ( 15 &lt; PCDAI &lt; =47.5 ) 3 . Ages 818 4 . Duration disease â‰¤ 36 month 5 . Active inflammation ( CRP &gt; 0.6 mg /dL ESR &gt; 20 Calprotectin &gt; 200 6 . Patients uncomplicated disease 7 . Patients disease involve terminal ileum small bowel past present 8 . Patients disease define L1 , L4 , L3 L2 limit cecum , ascend transverse colon Paris classification 9 . Signed informed consent 1 . Patients mild disease ( PCDAI 12.5 15 ) severe disease ( PCDAI &gt; 47.5 ) 2 . Pregnancy 3 . Patients disease confine colon involve descend colon , rectum sigmoid colon prior history small bowel involvement 4 . Patients active extra intestinal disease ( Arthritis , Uveitis , Pyoderma Gangrenosum , Erythema Nodosum etc . ) 5 . Patients complicated disease ( B2 , B3 ) 6 . Patients recently onset use immunomodulator &lt; 8 week , dose change past 8 week . 7 . Patients current use biologics , use last 8 week current use systemic steroid 8 . Patients active perianal disease ( active fistula abscess ) 9 . Patients positive stool culture relevant pathogen , , positive test parasites C. difficile . Stool test mandatory diarrhea present . 10 . Patients fever &gt; 38.3 11 . Documented milk protein allergy</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Exclusive Enteral Nutrition</keyword>
	<keyword>Diet</keyword>
	<keyword>Microbiome</keyword>
</DOC>